Highlights {#s1}
==========

-   Inhibitors for MEK decreased PGE~2~ and TXB~2~ production

-   Inhibitors for MEK and ERK decreased IL-8 secretion

-   JAK inhibitor tofacitinib increased PGE~2~ and TXB~2~ production

Introduction {#s2}
============

Inflammation is a highly controlled immune response to eliminate the cause of tissue injury or infection and to initiate tissue repair back to homeostasis *via* resolution ([@B25]; [@B8]). However, inflammation is not always terminated. Unresolved inflammation causes persistent pain, tissue degeneration, and loss of function. In particular, inflammatory responses drive many autoimmune diseases ([@B24]) and inflammation is a hallmark of cancer ([@B14]). Thus, there is a great need for new therapies that are anti-inflammatory and safe.

Prostaglandin E~2~ (PGE~2~) is a potent lipid mediator of inflammation and immune responses, and PGE~2~ is a central mediator of pain, edema, and cartilage erosion typically observed in the joints of rheumatoid arthritis patients ([@B2]; [@B13]). In addition, PGE~2~ is a promotor of the immunosuppressive tumor microenvironment with major impact on tumor progression ([@B33]; [@B14]; [@B28]). During inflammation, PGE~2~ is synthesized *via* conversion of arachidonic acid by cyclooxygenases (COX-1 and COX-2) into unstable PGH~2~ that is further metabolized by the inducible terminal synthase microsomal prostaglandin E synthase-1 (mPGES-1) to generate PGE~2~. Multiple non-steroidal anti-inflammatory drugs (NSAIDs) exist in clinical practice that unselectively decrease PGE~2~ production *via* inhibition of COX, but these drugs are all associated with adverse effects. Hence, selective inhibition of PGE~2~ production with small molecule inhibitors could therefore be a desirable therapeutic strategy in inflammation and cancer ([@B7]).

Interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. IL-8 signaling is implicated in multiple chronic inflammatory diseases ([@B29]) and cancer ([@B34]). For example, a recent meta-analysis concluded that patients suffering from systemic lupus erythematosus (SLE) have increased levels of circulating IL-8 ([@B21]). Patients with central neuropsychiatric SLE have increased concentration of IL-8 in cerebrospinal fluid compared to patients with non-central neuropsychiatric SLE ([@B35]). IL-8 is also associated with renal damage and pulmonary fibrosis in SLE patients ([@B20]; [@B26]). Given that IL-8 is a stimulant for neutrophil activation, which plays a significant role in the pathogenesis of SLE ([@B16]), targeting IL-8 secretion or signaling could constitute a therapeutic strategy for SLE. A similar role of neutrophils and net formation has been reported in patients with dermatomyositis (DM) ([@B37]; [@B27]). In cancer, IL-8 is highly expressed in several types of cancer tissues ([@B11]) and serum concentration of IL-8 correlates with tumor burden ([@B3]). The tumor-favoring actions of IL-8 include promotion of angiogenesis, increased survival of cancer stem cells, and attraction of myeloid cells that indorse the immunosuppressive tumor microenvironment ([@B3]).

In this study, we aimed to evaluate the effect of 57 chemical probes, high-quality tool compounds, and relevant control drugs on eicosanoid production and IL-8 secretion in human whole blood. A chemical probe is defined as "... a selective small-molecule modulator of a protein's function that allows the user to ask mechanistic and phenotypic questions about its molecular target in biochemical, cell-based or animal studies" ([@B4]), and these compounds follow the criteria of *in vitro* potency (IC~50~ or Kd \<100 nM), high selectivity versus other protein subfamilies (\>30-fold), and on-target cell activity at 1 µM. The chemical probes and other high-quality tool compounds included are mainly epigenetic modulators and kinase inhibitors that were produced in academic collaborations or donated by pharmaceutical companies within the Structural Genomic Consortium (SGC, [www.thesgc.org](www.thesgc.org)), which aims to investigate novel targets for drug development in open science and in collaboration with the pharmaceutical industry. These inhibitors were tested here at one concentration (in triplicates, n = 4--15 donors) based on previous knowledge of binding affinities and toxicity *in vitro*, as assessed using other validated assays in our laboratories (<https://ultra-dd.org/tissue-platforms/cell-assay-datasets>).

Materials and Methods {#s3}
=====================

Ethical Approval and Consent to Participate {#s3_1}
-------------------------------------------

Ethical approval for this study was granted by local research ethics committee at Karolinska University hospital (Dnr 02-196) and the Regional Ethical Review Board in Stockholm (Dnr 2015/2001-31/2). Full informed consent according to the Declaration of Helsinki was obtained from all patients.

Collection of Blood {#s3_2}
-------------------

Peripheral venous blood was drawn from 10 females and 6 males, aged between 27 and 81 years. Healthy controls (n = 4) and two patient groups were included: SLE (n = 9) and DM (n = 3). Patients with diagnosis SLE or DM and aged 18 or older were recruited from the Rheumatology Clinic at Karolinska University Hospital. Patients with ongoing treatment including Sendoxan (cyclophosphamide) and Benlysta (belimumab) or with kidney failure as defined by present dialysis or previous kidney transplantation were excluded. Disease activity measurements were not obtained at the time of sampling. For healthy control and patients characteristics, see [**Supplementary Table 1**](#ST1){ref-type="supplementary-material"}. The blood was collected in tubes containing sodium heparin (1000 U/ml).

Inhibitors {#s3_3}
----------

The inhibitors (chemical probes and other high-quality tool compounds) tested here were obtained through the SGC ([www.thesgc.org](www.thesgc.org)) and supplied by different distributers ([**Supplementary Table 2**](#ST2){ref-type="supplementary-material"}). Inhibitors and control drugs ([**Supplementary Table 2**](#ST2){ref-type="supplementary-material"}) were reconstituted at 10 mM in DMSO (D2250, Sigma-Aldrich), aliquoted in Eppendorf tubes or 96-well plates, and kept at −80°C. A fresh aliquot was used at each experiment. Diclofenac (dual COX-1/2 inhibitor) was used as positive control for inhibition of prostanoid production. Lipopolysaccharide (LPS; L6529, Sigma-Aldrich) was reconstituted in phosphate-buffered saline (PBS) (D8537, Sigma-Aldrich) to a final concentration of 0.1 mg/ml and kept at +8°C.

Whole Blood Assay {#s3_4}
-----------------

Inhibitors and vehicle control (DMSO) were diluted in PBS at room temperature with no direct light on. The treatments were prepared in 25 µl portions to U-shaped 96-well plate and 200 µl of freshly drawn heparin blood (\< 2 h at room temperature) was added to the plate. The plate was incubated at 37°C for 30 min and then 25 µl of 0.1 mg/ml LPS in PBS was added followed by pipetting up and down 3 times (final concentration of LPS was 10 µg/ml). The tested concentration for inhibitor was 0.1 or 1 µM ([**Supplementary Table 1**](#ST1){ref-type="supplementary-material"}). The plate was incubated for 24 h at 37°C and then centrifuged at 3000*g* for 10 min at 4°C. Working on ice, 100 µl plasma was recovered to a new plate (for prostanoid profiling) and from this 20 µl was transferred to a second plate (for IL-8 quantification). The plates were sealed with aluminum foil and stored at -80°C.

Extraction of Lipids {#s3_5}
--------------------

Plasma samples (80--240 µl) were thawed on ice and spiked with 50 µl deuterated internal standard mix containing 17 ng 6-keto-PGF~1α~-d4, 8 ng PGF~2α~-d4, 12 ng PGE~2~-d4, 8 ng PGD~2~-d4, 8 ng thromboxane B~2~ (TXB~2~)-d4, and 8 ng 15-deoxy-Δ12,14PGJ~2~-d4 (Cayman Chemical Company) prepared in 100% methanol. Protein precipitation was performed by addition of 800 µl 100% methanol, followed by vortexing, and centrifugation at 3000*g* for 10 min at 4°C. The supernatants were collected in a new plate and evaporated under vacuum for 4 h. The evaporated samples (100--200 µl) were diluted to 1 ml with 0.05% formic acid in water and then loaded onto Oasis HLB 1 cc 30 mg plate (Waters Corporation, USA) that had been pre-conditioned with 1 ml of 100% methanol and 1 ml of 0.05% formic acid in water. The plate was washed with 10% methanol, 0.05% formic acid in water and lipids were eluted with 100% methanol. The eluates were dried under vacuum overnight and stored at −20°C until reconstituted in 50 µl of 20% acetonitrile in water prior to analysis with liquid chromatography tandem mass spectrometry (LC-MS/MS).

Lipid Profiling by LC-MS/MS {#s3_6}
---------------------------

Lipids were quantified in negative mode with multiple reaction monitoring method, using a triple quadrupole mass spectrometer (Acquity TQ detector, Waters) equipped with an Acquity H-class UPLC (Waters). Eicosanoid were purchased from Cayman Chemicals and individually optimized for based on precursor ion m/z, cone voltage, collision energy, and fragment ion m/z ([**Supplementary Table 3**](#ST3){ref-type="supplementary-material"}). An eicosanoid mix containing all standards of interest was used to check interference in the LC-MS/MS analysis. Lysophophatidylcholine (LPC)(14:0) and LPC(18:0) were used to set optimal analytical parameters for quantification of LPCs. Separation of lipids was performed on a 50 × 2.1-mm Acquity UPLC BEH C18 column 1.7 µm (Waters) with a 12-min stepwise linear gradient (20%--95%) at a flowrate of 0.6 ml/min with 0.05% formic acid in acetonitrile as mobile phase B and 0.05% formic acid in water as mobile phase A. Data were analyzed using MassLynx software, version 4.1, with internal standard calibration and quantification to external standard curves for prostanoids. LPCs were normalized as area-% within each injection. Only lipids with peaks intensities of signal-to-noise greater than 10 (S/N \>10) were considered in our data analysis.

Development of Whole Blood Assay {#s3_7}
--------------------------------

The whole blood assay was developed to screen for changes in multiple eicosanoids. Each eicosanoid and corresponding deuterated variant were individually optimized in the LC-MS/MS analysis. A dilution curve containing 6-keto PGF~1α~-d4, PGE~2~-d4, PGD~2~-d4, PGF~2α~-d4, TXB~2~-d4, 15d-PGJ~2~-d4, LTB~4~-d4, LTC~4~-d5, LTD~4~-d5, 5-HETE-d8, 12-HETE-d8, 15-HETE-d8, and undeuterated variants of 13-HODE, RvD1, RvD2, 17-hydroxy DHA, and protectin DX was spiked into 100 µl plasma at different stages throughout the extraction. A dilution curve was spiked in water at the same step. The dilution curve ranged from 0.006 to 1.5 pmol as final amount injected on the column in the LC-MS/MS analysis. This enabled us to investigate the lower limit of quantification (LLOQ), recovery efficacy, and matrix effect for each eicosanoid. The LLOQ injected on column was considered as great (0.02--0.05 pmol), good (0.1--0.2 pmol), or poor (0.4--1.5 pmol). Eicosanoids with great LLOQ were PGE~2~, PGF~2α~, TXB~2~, RvD1, RvD2, LTB~4~, protectin DX, and 13-HODE; good LLOQ were 6-keto PGF~1α~, PGD~2~, 5-HETE, 15-HETE, and LTD~4~; poor LLOQ were 15d-PGJ~2~, 12-HETE, 17-hydroxy DHA, and LTC~4~. The extraction recovery rates were 33%--125%. The response in plasma compared to 20% acetonitrile were 52%--116% due to matrix effects. The estimated LLOQ in 100 µl plasma was approximately 1 ng/ml for the best performing eicosanoids including PGE~2~, TXB~2~, PGF~2α~, RvD1, RvD2, and protectin DX. We can conclude that the method provided similar quantitative performance in plasma for many eicosanoids.

LPS at 10 µg/ml induced PGE~2~ and TXB~2~ production in human whole blood, which are the two dominant eicosanoids produced under these conditions ([@B22]). All other eicosanoids were below the LLOQ. We chose 10 µg/ml of LPS based on the consensus in the literature for this type of assay, yielding a robust amount of PGE~2~ (49 ± 4 ng/ml, n = 5 donors) and TXB~2~ (24 ± 9 ng/ml, n = 5 donors). The prostanoid production was completely blocked using the dual COX-1/2 inhibitor diclofenac (10 µM). High concentration of DMSO (0.1%) slightly decreased PGE~2~ production by 20% (n = 2 donors) while DMSO at 0.01% or 0.001% had no effect. The intra-assay coefficient of variation (CV, n = 20 technical replicates) was 12% and 11% for PGE~2~ and TXB~2~, respectively. The inter-assay CV for control material (n = 3 donors) was 20% for PGE~2~ and 30% for TXB~2~. This was performed on blood that was drawn, incubated, extracted, and analyzed at separate occasions. The suppression in signal due to matrix effects and/or recovery efficiency varied between donors and experiments, ranging from 10% to 70% suppression compared to signal in extracted blank (mean ± SD, n = 6 donors, PGE~2~: 45% ± 25%, TXB~2~: 40 ± 20%). In summary, 24-h incubation of whole blood with 10 µg/ml LPS resulted in profound induction of the COX-1/2 products PGE~2~ and TXB~2~ that was efficiently blocked by diclofenac at 10 µM.

Quantification of IL-8 {#s3_8}
----------------------

IL-8 was quantified in plasma by human IL-8 (CXCL8) enzyme-linked immunosorbent assay (ELISA) development kit (3560-1H, Mabtech) according to manufacturer's instructions.

Statistical Analyses {#s3_9}
--------------------

Data are presented as mean ± SEM if not stated otherwise. Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). One-sample t-test and two-sample t-test with Bonferroni correction were used to test significant difference. Statistical significance level was set to p \< 0.05.

Results {#s4}
=======

Effect on PGE~2~ and TXB~2~ Production {#s4_1}
--------------------------------------

Our screening of inhibitors suggested that selected kinase inhibitors affected prostanoid production ([**Figure 1**](#f1){ref-type="fig"}). The strongest reduction in PGE~2~ production was observed by MEK-1 inhibitor PD0325901 (31% ± 6%, p = 0.001, n = 4) and MEK-1/2 inhibitor trametinib (34% ± 7%, p \< 0.0001, n = 15). Moderate suppression in PGE~2~ concentration was found for MEK-1/2 inhibitor selumetinib (65% ± 9%, p = 0.02, n = 5), ERK-1/2 inhibitor SCH772984 (76% ± 11%, p = 0.04, n = 13), and p38 inhibitor skepinone-L (76% ± 8%, p = 0.01, n = 13). However, the tested p38 inhibitor pamapimod did not affect PGE~2~ production. Two of these compounds decreased TXB~2~ production, namely trametinib (63% ± 6%, p = 0.02, n = 15) and selumetinib (74% ± 7%, p = 0.02, n = 5). Diclofenac, here used as a positive control for inhibition of prostanoid production, blocked the prostanoid production while selective COX-2 inhibitor NS-398 inhibited only PGE~2~ production, in agreement with previously reported data for these compounds in whole blood assay ([@B18]). The JAK inhibitor tofacitinib increased both PGE~2~ (286% ± 51%, p = 0.01, n = 6) and TXB~2~ (169% ± 20%, p = 0.02, n = 6) production. The IRAK-1/4 inhibitor I slightly increased the concentrations of PGE~2~ (139% ± 15%, p = 0.04, n = 7) and TXB~2~ (133% ± 8%, p = 0.008, n = 7).

![Volcano plots showing effects on PGE~2~ **(A)** and TXB~2~ **(B)** production in LPS-induced human whole blood. The top altered conditions compared to vehicle control based on fold-change (\< 0.5 or \>2) and p-value (\< 0.05) are highlighted. Each inhibitor was tested in 4--15 donors. Statistical significance was tested using one-sample t-test (p \< 0.05). PGE~2~, prostaglandin E~2~; LPS, lipopolysaccharide; TXB~2~, thromboxane B~2~.](fphar-11-00613-g001){#f1}

We chose to investigate the strongest observed effects in more detail by performing concentration--response experiments for PD0325901, trametinib, selumetinib, and tofacitinib. All three MEK inhibitors showed a concentration-dependent response on both PGE~2~ and TXB~2~ production while tofacitinib showed a concentration-dependent response on PGE~2~ production ([**Figure 2**](#f2){ref-type="fig"}).

![Validation of inhibitory effect on PGE~2~ **(A)** and TXB~2~ **(B)** production by MEK inhibitors in human whole blood. Diclofenac at 10 µM was used as positive control. Data are presented as mean ± SD of biological replicates (n = 2-6 per condition) from one representative experiment. The absolute prostanoid production in LPS control was 53.3 ± 8.3 ng/ml for PGE~2~ and 15.5 ± 2.1 ng/ml for TXB~2~. The concentration--response was tested in two donors. Statistical significance was tested using two-sample t-test with Bonferroni correction (p \< 0.05). The asterisk (\*) represents statistical significance to vehicle control.](fphar-11-00613-g002){#f2}

Effect on IL-8 Secretion {#s4_2}
------------------------

In line with the effect on prostanoid production, reduction in IL-8 secretion was found for PD0325901 (24% ± 9%, p = 0.03, n = 3), trametinib (27% ± 5%, p \< 0.0001, n = 13), and selumetinib (45% ± 10%, p = 0.03, n = 3) ([**Figure 3**](#f3){ref-type="fig"}). Moderate reduction in IL-8 secretion was found for SCH772984 (62% ± 9%, p = 0.002, n = 12) and diclofenac (66% ± 8%, p = 0.003, n = 11). We could also observe that tofacitinib increased IL-8 secretion (225% ± 57%, p = 0.16, n = 3), however not with statistical significance.

![Volcano plot showing effects on IL-8 secretion in LPS-induced human whole blood. The top altered conditions compared to vehicle control based on fold-change (\< 0.5 or \>2) and p-value (\< 0.05) are highlighted. Each inhibitor was tested in 3--13 donors. Statistical significance was tested using one sample t-test (p \< 0.05). IL-8, interleukin-8.](fphar-11-00613-g003){#f3}

Effect on LPC Profile {#s4_3}
---------------------

We measured LPC species within our targeted LC-MS/MS analysis. LPCs are mainly generated by metabolism of membrane phosphatidylcholine by cytosolic phospholipase A~2~ ([@B9]). These lipids have been reported to be involved in several cellular processes; sometimes with opposing effect depending on degree of saturation, concentration, and biological context ([@B31]; [@B12]). We observed no difference in total LPC or LPC profile when whole blood was treated with LPS neither did any of the tested inhibitors alter the LPC profile ([**Figure 4**](#f4){ref-type="fig"}).

![Effect on LPC profile in whole blood. There was no difference in total LPC **(A)** or LPC profile **(B)** with LPS treatment, and none of the tested compounds affected the LPC profile **(C)**. Each inhibitor was tested in 4--15 donors. LPC, lysophophatidylcholine.](fphar-11-00613-g004){#f4}

Discussion {#s5}
==========

We have tested the inhibitory effect on prostanoid production and IL-8 secretion in human whole blood for 57 high-quality inhibitors with known target specificities and *in vitro* potencies. None of the tested epigenetic modulators, which are acting on demethylases, bromodomains, or methyltransferases, affected PGE~2~ or IL-8 concentration. Inhibition of MEK-1/2 or ERK decreased PGE~2~ production and IL-8 secretion in this assay. This effect was observed for allosteric inhibitor trametinib (MEK-1/2), non-ATP-competitive inhibitors PD0325901 (MEK-1) and selumetinib (MEK-1/2), and ATP-competitive inhibitor SCH772984 (ERK-1/2). These kinase targets are part of the RAS/RAF/MEK/ERK signaling transduction pathway, where inhibition of MEK prevents the downstream phosphorylation and activation of ERK that ultimately regulates cellular responses such as survival, lipid metabolism, and protein translation ([@B23]). For example, MEK-1/2 inhibitor PD184352 decreased PGE~2~ production in melanoma cell line by decreased COX-2 expression due to inhibition of phosphorylation on ERK ([@B36]) and trametinib reduced IL-8 production in melanoma cell line ([@B15]). We found that our positive control diclofenac for blocking prostanoid production decreased IL-8 secretion, which is explained by the fact that PGE~2~ stimulates IL-8 production in cultured cells ([@B1]; [@B10]; [@B5]; [@B32]). While our study mainly focused on identifying inhibitory effects, we observed that JAK inhibitor tofacitinib increased both PGE~2~ production and IL-8 secretion. Tofacitinib is used to treat rheumatoid arthritis and it is known that tofacitinib can increase the expression of pro-inflammatory mediators, including PGE~2~, in macrophages by acting inhibitory on the expression of anti-inflammatory IL-10 ([@B17]). The increased formation of pro-inflammatory PGE~2~ and platelet activating thromboxane A~2~ (as measured by stable metabolite TXB~2~) in human whole blood may be associated with the recently recognized increased risk of thromboembolism associated with JAK inhibitors in treatment of rheumatoid arthritis ([@B30]). Moreover, we did not observe any changes in LPC profile by LPS alone or the tested compounds. While LPCs can be generated by degradation of phosphatidylcholine, LPCs are continuously incorporated back into the plasma membrane ([@B19]). This would result in no net change in LPCs while other phospholipid species may change in abundance. We acknowledge that the limitation of our study is the usage of one concentration per tested inhibitor. However, the used concentrations were based on reported IC~50~ and/or EC~50~ values as well as solid experiences in our laboratories using other validated assay systems (<https://ultra-dd.org/index.php/tissue-platforms/cell-assay-datasets>). The concentrations were selected to avoid cellular toxicity but we acknowledge that greater concentrations might be of relevance considering the bioavailability in blood. Indeed, we demonstrated in concentration--response experiments that greater inhibitory effect could be achieved by increasing the concentration for the MEK inhibitors. However, this increases the risk of off-target effects and/or introduction of cellular toxicity that needs to be taken into account in experimental design and interpretation of results. In conclusion, we identified inhibitors for MEK or ERK as anti-inflammatory hits in our human whole blood assay. Based on the suppression in PGE~2~ production and IL-8 secretion, further investigation of the MEK/ERK signaling pathway may inform future therapeutic strategies to treat inflammatory diseases such as SLE and DM.
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